Abstract:ID 90930 Poster Board 516 Text Parkinson's disease (PD) is a prevalent neurodegenerative condition characterized by degeneration of dopaminergic neurons in the substantia nigra of the midbrain. This results in bradykinesia, tremors, rigidity, and other motor and non-motor deficits. The prevalence of PD is increasing, in part, due to the aging population. Despite this growing burden, the development of effective therapies to halt disease progression remains an unmet need. This challenge is due to gaps in our understanding of the molecular mechanisms underlying the disease and deficiencies of preclinical models in recapitulating all aspects of the pathobiology of PD. Consequently, deepening our understanding of pathobiology and discovering druggable targets remain a research priority. Herein, we describe assay development and optimization of a high throughput phenotypic screen in the roundworm Caenorhabditis elegans for discovery of novel druggable targets and genetic influencers of neurodegeneration and neuroprotection. We utilized two transgenic C. elegans strains expressing human PD-linked genes—one with mutant (A53T) alpha-synuclein (SNCA) and the other expressing mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2). These strains exclusively express the PD-related transgenes and green fluorescent protein (GFP) in their dopaminergic neurons, facilitating the tracking of neurodegeneration through measurable changes in the GFP fluorescence. Using laser cytometry and high content imaging with worms growing in liquid culture within 384-well plates, we assessed the health of the dopamine neurons via GFP intensity, number of neurons, and area of green objects. We observed a 30-50% and 75-85% decrease in GFP intensity in the SNCA and LRRK2 worms, respectively, by day seven compared to wild-type controls lacking the PD genes but expressing GFP exclusively in the dopaminergic neurons. We crossed the worms to RNAi hypersensitive backgrounds carrying eri-1, rrf-3, and eri-1;lin-15B mutations to overcome the typical resistance to neuronal RNAi knockdown in C. elegans . We observed a robust RNAi knockdown in the control and mutant worms with a 50-75% knockdown on day seven with RNAi against GFP, ama-1, ceh-43, and unc-62 compared to empty vector control. RNAi specifically engineered against the LRRK2 transgene slows neurodegeneration in the LRRK2 mutant worms. Additionally, we have identified selective LRRK2 kinase inhibitors that confer neuroprotection in the LRRK2-carrying worms with promising properties to serve as controls for high throughput molecular library screening. Further optimization studies are ongoing with the goal of conducting a screen for genes influencing neuroprotection in these models. Additionally, we plan to conduct a small molecule library screen for novel neuroprotective compounds using these PD models. These lines of inquiry may identify new molecules or potential druggable targets for novel therapeutics for influencing neurodegeneration and PD progression. Supported by the NINDS Intramural Research Program.

A drug discovery pipeline for MAPK/ERK pathway inhibitors in C. elegans

Using Caenorhabditis elegans is to study the antitumor drug screening model of the Ras/MAPK signaling pathway

Neuroprotection in C. Elegans Parkinsons Disease Models: Discovering Therapeutic Insights via RNAi and Small Molecule High Throughput Screening

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs

A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans

A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans

Model-based Analysis of Response and Resistance Factors of Cetuximab Treatment in Gastric Cancer Cell Lines

Combined flow cytometry and high-throughput image analysis for the study of essential genes in Caenorhabditis elegans

A Mouse Model for the Rapid and Binomial Assessment of Putative WNT/β-Catenin Signalling Inhibitors

Translational modeling for patients with RAS mutant tumors: Profiling the dual-MEK inhibitor IMM-1-104 in a humanized 3D assay.

Abstract 5902: Targeting MAPK-driven tumors via inhibition of MAP2K4

A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action

Development of a pipeline to evaluate YAP-TEAD inhibitor potential - direct TEAD inhibition represses cancerous growth in a NF2-mutant model of mesothelioma

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Implications of trinodal inhibitions and drug repurposing in MAPK pathway: A putative remedy for breast cancer

Structure activity relationship and target prediction for ABX464 analogues in Caenorhabditis elegans

Biophysical phenotyping of C. elegans in a microfluidic chip for high-throughput drug screening

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity

Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas

Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology